RSS
10 Nov 2020

Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections

Author: admintech | Filed under: Press Release

MORRISVILLE, N.C., Nov. 10, 2020 /PRNewswire/ –Locus Biosciences, a clinical-stage biopharmaceutical company, announced today that it has signed a contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to fund up to $12.5…

This entry was posted on Tuesday, November 10th, 2020 at 7:16 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»